Search research articles
Contact Us
Filters
Showing results (141-150 of 203) with videos related to
Page
of 21
Sort By:
JAMA Dermatology
|
February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial
Andrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Journal of Pediatric Orthopedics
|
August 28, 2020
Are Some Randomized Clinical Trials Impossible?
Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
Joanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer
|
November 14, 2025
The impact of focused federal initiatives on pediatric cancer research
Subhashini Jagu, Malcolm A Smith, Nita L Seibel, et al.
Neurology
|
August 17, 2016
Current status and recommendations for biomarkers and biobanking in neurofibromatosis
C Oliver Hanemann, Jaishri O Blakeley, Fabio P Nunes, et al.
Neurology
|
July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2
Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Neurology. Genetics
|
August 11, 2021
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Journal of the National Cancer Institute
|
October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2
Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Page
of 21
Search research articles
Search
Showing results (141-150 of 203) with videos related to
Sort By:
Page
of 21
JAMA Dermatology
|
February 26, 2025
Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial
Andrea M Gross, Olivia H Reid, Lauren A Baldwin, et al.
Journal of Pediatric Orthopedics
|
August 28, 2020
Are Some Randomized Clinical Trials Impossible?
Jonathan J Rios, B Stephens Richards, David A Stevenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 13, 2016
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
Joanne P Lagmay, Mark D Krailo, Ha Dang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer
|
November 14, 2025
The impact of focused federal initiatives on pediatric cancer research
Subhashini Jagu, Malcolm A Smith, Nita L Seibel, et al.
Neurology
|
August 17, 2016
Current status and recommendations for biomarkers and biobanking in neurofibromatosis
C Oliver Hanemann, Jaishri O Blakeley, Fabio P Nunes, et al.
Neurology
|
July 7, 2021
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2
Srivandana Akshintala, Nashwa Khalil, Kaleb Yohay, et al.
Neurology. Genetics
|
August 11, 2021
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1
Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
Jaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Journal of the National Cancer Institute
|
October 21, 2004
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2
Brigitte C Widemann, Frank M Balis, Aiman Shalabi, et al.
Page
of 21